Program
etrasimod
Also written as “Etrasimod”, “APD334” and “Etrasimod Immediate Release (IR)”.
Its studies are mostly in Colitis, Ulcerative · Dermatitis, Atopic · Crohn Disease · Alopecia Areata · Eosinophilic Esophagitis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 203 open or running | phase 3since May 8, 2019 | May 13, 2015 | Jun 16, 2029phase 2 · NCT05287126 |
| Everstar Therapeutics | 11 open or running | phase 3since Nov 22, 2019 | Nov 22, 2019 | none ahead |
Also a collaborator on its studies: arena-is-a-wholly-owned-subsidiary-of-pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since May 13, 2015.
- Jun 21, 2019Phase 3 study in Colitis, UlcerativePfizer · NCT03996369 · 354 enrolled · United States, Argentina, Australia and more
- Nov 12, 2019Phase 2 study in Dermatitis, AtopicPfizer · NCT04162769 · 140 enrolled · United States, Australia, Canada
- Nov 20, 2019Phase 3 study in Crohn DiseasePfizer · NCT04173273 · 379 enrolled · United States, Argentina, Australia and more
- Nov 22, 2019Everstar Therapeutics's first study: phase 3 study in Moderately to Severely Active Ulcerative ColitisNew to Everstar TherapeuticsEverstar Therapeutics · NCT04176588 · 341 enrolled · China
- Sep 15, 2020Phase 2 study in Alopecia AreataPfizer · NCT04556734 · 80 enrolled · United States, Canada
- Oct 23, 2020Phase 2 study in Colitis, UlcerativePfizer · NCT04607837 · 234 enrolled · United States, Australia, Belarus and more
- Dec 19, 2020Phase 2 study in Eosinophilic EsophagitisPfizer · NCT04682639 · 108 enrolled · United States, Australia, Belgium and more
- Jan 11, 2021Phase 3 study in Colitis, UlcerativePfizer · NCT04706793 · 42 enrolled · Japan
- Sep 20, 2021Phase 2 study in Colitis, UlcerativePfizer · NCT05061446 · 54 enrolled · Japan
- Mar 10, 2022Phase 2 study in Colitis, UlcerativePfizer · NCT05287126 · 36 planned · United States, Japan, Poland and more
- Dec 22, 2022Phase 3 study in Dermatitis, AtopicPfizer · NCT05732454 · 58 enrolled · United States, Canada, Czechia and more
- Nov 15, 2023Phase 1 study in Healthy ParticipantsPfizer · NCT06140290 · 8 enrolled · Belgium
- Aug 5, 2025Phase 1 study in Healthy ParticipantPfizer · NCT07153159 · 8 enrolled · Belgium
- Mar 10, 2026Phase 2 study in Colitis, UlcerativePfizer · NCT07470879 · 24 planned · United States, Australia, Canada and more
Ahead
- Jun 16, 2029Primary completion: phase 2 study in Colitis, UlcerativePfizer · NCT05287126
- Jun 19, 2029Primary completion: phase 3 study in Colitis, UlcerativePfizer · NCT03950232
- Sep 8, 2030Primary completion: phase 2 study in Colitis, UlcerativePfizer · NCT07470879
TargetBeta
“Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor Edg-8 modulator”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fingolimodrule | Novartis | phase 4 | 55 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07470879Colitis, Ulcerative · United States, Australia, Canada and more | 2 | Recruiting | Pfizer | Sep 8, 2030 | 24 |
| NCT07153159Healthy Participant · Belgium | 1 | Completed | Pfizer | Sep 18, 2026 | 8 |
| NCT06140290Healthy Participants · Belgium | 1 | Completed | Pfizer | Mar 1, 2024 | 8 |
| NCT05732454Dermatitis, Atopic · United States, Canada, Czechia and more | 3 | Terminated | Pfizer | Apr 29, 2024 | 58 |
| NCT05287126Colitis, Ulcerative · United States, Japan, Poland and more | 2 | Recruiting | Pfizer | Jun 16, 2029 | 36 |
| NCT05061446Colitis, Ulcerative · Japan | 2 | Completed | Pfizer | Oct 6, 2023 | 54 |
| NCT04706793Colitis, Ulcerative · Japan | 3 | Completed | Pfizer | Aug 3, 2022 | 42 |
| NCT04682639Eosinophilic Esophagitis · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Sep 30, 2022 | 108 |
| NCT04607837Colitis, Ulcerative · United States, Australia, Belarus and more | 2 | Completed | Pfizer | Jun 19, 2024 | 234 |
| NCT04556734Alopecia Areata · United States, Canada | 2 | Completed | Pfizer | Jun 7, 2023 | 80 |
| NCT04176588Moderately to Severely Active Ulcerative Colitis · China | 3 | Active, not recruiting | Everstar Therapeutics | Jul 2024 | 341 |
| NCT04173273Crohn Disease · United States, Argentina, Australia and more | 3 | Terminated | Pfizer | Apr 23, 2025 | 379 |
| NCT04162769Dermatitis, Atopic · United States, Australia, Canada | 2 | Completed | Pfizer | Sep 9, 2020 | 140 |
| NCT03996369Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Dec 7, 2021 | 354 |
| NCT03950232Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Jun 19, 2029 | 896 |
| NCT03945188Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Feb 8, 2022 | 433 |
| NCT03155932Liver Cirrhosis, Biliary · United States, Australia, New Zealand | 2 | Terminated | Pfizer | Jan 31, 2019 | 2 |
| NCT03139032Inflammatory Bowel Diseases · Belgium, Germany, Serbia | 2 | Terminated | Pfizer | Dec 6, 2017 | 1 |
| NCT03072953Pyoderma Gangrenosum · Australia, New Zealand | 2 | Terminated | Pfizer | May 22, 2018 | 2 |
| NCT02536404Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Completed | Pfizer | Nov 1, 2018 | 118 |
| NCT02447302Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Completed | Pfizer | Feb 14, 2018 | 156 |
How it is read
Names in the registry
- “Etrasimod”, 19 entries
- “APD334”, 3 entries
- “etrasimod”, 1 entry
- “Etrasimod Immediate Release (IR)”, 1 entry
- “Etrasimod 1 mg”, 1 entry
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 11 studies
- Dermatitis, Atopic, 2 studies
- Crohn Disease, 1 study
- Alopecia Areata, 1 study
- Eosinophilic Esophagitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.